SDZ 220-581 hydrochloride_product_DataBase

Bioactivity	SDZ 220-581 hydrochloride is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7[1].
Target	pKi: 7.7 (NMDA receptor)
In Vivo	SDZ 220-581 (3.2-32 mg/kg; oral administration; for 24 hours; male OF-l mice) treatment dose-dependently protects mice against maximal electroshock seizures (MES). The time-course of protection by SDZ 220-581 is characterized by a rapid onset and long duration of action[1]. Animal Model:
Name	SDZ 220-581 hydrochloride
CAS	179411-93-9
Formula	C16H18Cl2NO5P
Molar Mass	406.20
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Urwyler S, et al. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):655-69. [2]. Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39.

PeptideDB